Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)

  • Technology appraisal
  • TA987
  • Published: 

Register as a stakeholder

This guidance has been updated and replaced by NICE's technology appraisal guidance 1159 (TA1159).